Skip to main
HUM

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 17%
Buy 22%
Hold 56%
Sell 0%
Strong Sell 6%

Bulls say

Humana is currently in a strong position with its niche focus on government-sponsored healthcare programs, as well as its wide range of healthcare services. They have shown strong performance in terms of medical membership and closely monitor their financials to maintain their targeted margins. With upcoming catalysts such as the launch of plan finder and release of Star Ratings, the company is well-positioned for future growth.

Bears say

Humana is highly reliant on government-sponsored programs for nearly all of its medical membership, with limited exposure to commercial insurance. The company faces margin pressure from rising medical costs and potential benefit cuts, which could hinder its ability to regain normalized margins in the next decade. The uncertainty surrounding industry thresholds and potential adjustments in the Medicare Advantage program also add to the complexity and risk of investing in this stock. Additionally, Humana's current valuation of 15.5x 2027E EPS may be too optimistic, considering the company's challenges and potential impacts on its core operating performance.

Humana (HUM) has been analyzed by 18 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 22% recommend Buy, 56% suggest Holding, 0% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Hold based on their latest research and market trends.

According to 18 analysts, Humana (HUM) has a Hold consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $373.72, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $373.72, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.